Cadrenal Therapeutics files prospectus supplement for up to $3.4M ATM offering

Cadrenal Therapeutics, Inc.

Filed prospectus supplement to sell up to $3,438,062 of common stock via ATM program with H.C. Wainwright.
As of Nov 18, 2025, $9,386,964 of common stock already sold under the same ATM agreement dated March 11, 2024.
Wainwright will receive 3.0% commission on gross sales; Company has no obligation to sell shares.
Legal opinion from Blank Rome LLP attached as Exhibit 5.1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.